☆ 4.6 Article

Prognostic prediction of clear cell renal cell carcinoma based on lipid metabolism-related lncRNA risk coefficient model

FRONTIERS IN GENETICS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Identification of metabolism-related long non-coding RNA (lncRNA) signature predicts prognosis and immune infiltrates in hepatocellular carcinoma

Xiaodong Wang et al.

Summary: The metabolism-related lncRNA signature is a promising biomarker for distinguishing the prognosis and immune characteristics of HCC. The multigene signature based on these lncRNAs can effectively differentiate high-risk and low-risk groups and exhibits good predictive performance.

ANNALS OF TRANSLATIONAL MEDICINE (2022)

添加到收藏夹

Article Genetics & Heredity

A novel lipid metabolism-related lncRNA signature predictive of clinical prognosis in cervical cancer

Yanzhen Lu et al.

Summary: In this study, a novel lipid metabolism-related five-lncRNA signature was established based on the analysis of lncRNA expression profiles in Cervical cancer patients, and its predictive value for overall survival was confirmed. Risk score, cancer stage, pregnancy, and BMI were also identified as independent factors with prognostic value. Furthermore, the expression of these five lncRNAs was found to be associated with the tumor immune microenvironment.

FRONTIERS IN GENETICS (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

LncRNA regulation: New frontiers in epigenetic solutions to drug chemoresistance

Ying Zhou et al.

Summary: Long-noncoding RNAs (lncRNAs) play a role in regulating cancer cell sensitivities to drugs by interacting with epigenetic controllers, leading to gene expression and drug resistance. Epigenetic signatures are effective biomarkers for monitoring therapeutic effects, while the regulatory mechanism between lncRNAs and epigenetic machinery can be a new target for overcoming drug resistance.

BIOCHEMICAL PHARMACOLOGY (2021)

添加到收藏夹

Article Medicine, Research & Experimental

LncRNA ZFAS1: Role in tumorigenesis and other diseases

Soudeh Ghafouri-Fard et al.

Summary: ZFAS1, a long non-coding RNA located on chromosome 20q13.13, is involved in the development of both neoplastic and non-neoplastic disorders, and is considered an oncogene in almost all types of cancers.

BIOMEDICINE & PHARMACOTHERAPY (2021)

添加到收藏夹

Review Oncology

Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma

Bryce R. Christensen et al.

Summary: The treatment for metastatic renal cell carcinoma has evolved significantly in recent years, with options including local therapy, active surveillance, and targeted therapy. Combination regimens with ICI are the most effective and ongoing studies aim to optimize treatment selection for personalized disease management.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2021)

添加到收藏夹

Editorial Material Urology & Nephrology

The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care

Jens Bedke et al.

Summary: The recent trials have shown improved survival benefits with immune checkpoint inhibitor combinations in advanced kidney cancer, particularly with lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, axitinib plus pembrolizumab, and ipilimumab plus nivolumab. These combination therapies are recommended as first-line treatments for advanced kidney cancer.

EUROPEAN UROLOGY (2021)

添加到收藏夹

Article Oncology

Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma

Kevin Bi et al.

Summary: The study shows that immune checkpoint blockade (ICB) remodels the RCC microenvironment and modifies the interplay between cancer and immune cell populations, critical for understanding response and resistance to ICB.

CANCER CELL (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

ciRS-7 is a prognostic biomarker and potential gene therapy target for renal cell carcinoma

Weipu Mao et al.

Summary: ciRS-7 is highly expressed in RCC and acts as a tumor promoter by regulating the miR-139-3p/TAGLN axis and activating the PI3K/AKT signaling pathway to promote RCC progression and metastasis. PBAE/si-ciRS-7 nanocomplexes can significantly inhibit RCC tumor progression and metastasis, representing a promising gene therapeutic strategy.

MOLECULAR CANCER (2021)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma

Yuexin Xu et al.

Summary: This review highlights the central role of T-cell immunity in the treatment of advanced RCC, providing an overview of clinical outcomes for antigen-targeted vaccines and other T-cell-engaging therapies. Emerging strategies to enhance the effectiveness of antigen-specific therapy for RCC are also discussed.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)

添加到收藏夹

Article Health Care Sciences & Services

The lncRNA Signatures of Genome Instability to Predict Survival in Patients with Renal Cancer

Liang Huang et al.

Summary: This study assessed the impact of lncRNAs on genome instability in renal cancer and identified three lncRNAs (AC156455.1, AC016405.3, and LINC01234) associated with patient survival, leading to the development of a prognostic model. The model, GlncScore, accurately predicted patient survival and reflected genome instability, suggesting its potential as a new biomarker for renal cancer.

JOURNAL OF HEALTHCARE ENGINEERING (2021)

添加到收藏夹

Review Oncology

Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC

Fabio Turco et al.

Summary: Obesity is a well-known risk factor for renal cell carcinoma development, but studies have found that it may actually be associated with a better prognosis in patients with this type of cancer, a phenomenon known as the obesity paradox. The purpose of research in this area is to better understand the mechanisms behind this paradoxical relationship.

ENDOCRINE-RELATED CANCER (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Serum and urine analysis with gold nanoparticle-assisted laser desorption/ionization mass spectrometry for renal cell carcinoma metabolic biomarkers discovery

Adrian Arendowski et al.

Summary: This pilot study utilized gold nanoparticle enhanced target surface assisted-laser desorption/ionization mass spectrometry (SALDI MS) to analyze serum and urine samples from kidney cancer patients, identifying potential biomarkers for distinguishing different types, grades, and stages of human RCC.

ADVANCES IN MEDICAL SCIENCES (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

The Role of lncRNA in the Development of Tumors, including Breast Cancer

Beata Smolarz et al.

Summary: Long noncoding RNAs (lncRNAs) are a large group of ribonucleic acids and play a crucial role in the development of cancers, including breast carcinoma. Their disrupted expression has been linked to the pathogenesis of various diseases.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Epigenetic Biomarkers of Renal Cell Carcinoma for Liquid Biopsy Tests

Raimonda Kubiliute et al.

Summary: Renal cell carcinomas (RCC) represent 2-3% of global cancer burden and have the highest mortality rate among genitourinary cancers. Liquid biopsies, containing tumor-derived nucleic acids, show promise as non-invasive biomarkers for early cancer detection and personalized treatment. Validation and discovery of novel RCC biomarkers with improved performance and clinical utility is essential for translation into clinical practice.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Medical Laboratory Technology

Immune-related eight-lncRNA signature for improving prognosis prediction of lung adenocarcinoma

Yan Chen et al.

Summary: The study integrated a machine-learning framework to identify LUAD-related lncRNA survival biomarkers, and discovered an eight-lncRNA signature including NPSR1-AS1, SATB2-AS1, LINC01090, etc., which contributes to predicting patient's prognosis risk and survival outcomes. Furthermore, parsing LUAD tumor immune infiltration and constructing the ceRNA network revealed the close association of these lncRNAs with immune cell infiltration and MHC molecule expression.

JOURNAL OF CLINICAL LABORATORY ANALYSIS (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

LncRNA as a multifunctional regulator in cancer multi-drug resistance

Jiaying He et al.

Summary: Long non-coding RNAs (lncRNAs) are closely related to cancer drug resistance by regulating gene expression, participating in multiple mechanisms, and may serve as potential therapeutic targets for cancer treatment.

MOLECULAR BIOLOGY REPORTS (2021)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Noncoding RNA therapeutics - challenges and potential solutions

Melanie Winkle et al.

Summary: In recent years, RNA-based therapies have gained FDA approval, but there are still challenges in targeting ncRNAs. Therapeutic targeting of noncoding RNAs has the potential to become a new approach for treating diseases such as cancer.

NATURE REVIEWS DRUG DISCOVERY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response

Yuping Zhang et al.

Summary: This study used single-cell RNA sequencing to identify the cell of origin for different RCC subtypes and highlighted the crucial role of the tumor microenvironment in influencing ccRCC biology and response to therapy.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

添加到收藏夹

Article Genetics & Heredity

LncRNA FENDRR Expression Correlates with Tumor Immunogenicity

Maria Cristina Munteanu et al.

Summary: FENDRR is a recently discovered tumor suppressor long non-coding RNA associated with epigenetic modulation of target genes involved in tumor immunity. Its expression levels correlate with the expression of immune activation genes and MHC-I molecules in tumor cells. Modulation of FENDRR expression enhances inflammatory and WNT signaling pathways in tumors, suggesting a potential role in the development of immune-relevant phenotypes and improvement of cancer immunotherapy.

GENES (2021)

添加到收藏夹

Article Immunology

Tumor-Experienced Human NK Cells Express High Levels of PD-L1 and Inhibit CD8+ T Cell Proliferation

Jessica M. Sierra et al.

Summary: NK cells in clear cell renal cell carcinoma patients display altered phenotype and impaired effector functions, with a high frequency of tumor-infiltrating PD-L1(+) NK cells suggesting immunoregulatory functions. In vitro studies show that PD-L1(hi) NK cells exhibit an activated phenotype and enhanced effector functions, while also inhibiting CD8(+) T cell proliferation in a PD-L1-dependent manner.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Renal Lipid Metabolism Abnormalities in Obesity and Clear Cell Renal Cell Carcinoma

Ion Alexandru Bobulescu et al.

Summary: Clear cell renal cell carcinoma is the most common and deadly type of kidney cancer, characterized by large intracellular lipid deposits believed to result from lipid metabolic reprogramming in tumor cells. Obesity is an independent risk factor for this cancer, and may be linked to lipid accumulation and metabolic disturbances in noncancerous cells of the kidney.

METABOLITES (2021)

添加到收藏夹

Review Oncology

First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis

Fahad Quhal et al.

Summary: The study performed indirect comparisons of first-line immune checkpoint inhibitor (ICI)-based combination therapies for metastatic renal cell carcinoma (mRCC), revealing the advantages and disadvantages of different therapeutic combinations. The findings suggest that combinations of ICIs and tyrosine kinase inhibitors (TKIs) may provide superior treatment options in the first-line setting, while ICI-ICI combinations could be optimal for tumors with increased PD-L1 expression.

EUROPEAN UROLOGY ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Quantitative proteomic analysis reveals sophisticated metabolic alteration and identifies FMNL1 as a prognostic marker in clear cell renal cell carcinoma

Gui Mal et al.

Summary: The study revealed a sophisticated metabolic reprogramming in ccRCC, with upregulation of rate-limiting enzymes in glycolysis and mitochondrial impairment. FMNL1 was identified as a potential prognostic marker in ccRCC, and knockdown of FMNL1 inhibited cell proliferation, migration, and invasion.

JOURNAL OF CANCER (2021)

添加到收藏夹

Review Oncology

Long noncoding RNAs in cancer metastasis

S. John Liu et al.

Summary: Long noncoding RNAs play crucial roles in promoting metastasis by participating in discrete pro-metastatic steps and influencing the metastatic tumor microenvironment. They have the potential for diagnostic and therapeutic applications, but also face controversies and ongoing technical challenges. Further research is needed to explore their mechanisms and potential as targets for novel therapies in cancer metastasis.

NATURE REVIEWS CANCER (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Ensembl 2020

Andrew D. Yates et al.

NUCLEIC ACIDS RESEARCH (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Integration of Lipidomics and Transcriptomics Reveals Reprogramming of the Lipid Metabolism and Composition in Clear Cell Renal Cell Carcinoma

Giuseppe Lucarelli et al.

METABOLITES (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies

Yi Xiao et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

添加到收藏夹

Letter Oncology

Statistical predictions with glmnet

Solveig Engebretsen et al.

CLINICAL EPIGENETICS (2019)

添加到收藏夹

Editorial Material Cell Biology

EPIGENETICS Guardians of the oocyte methylome

Kim Baumann

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)

添加到收藏夹

Article Oncology

Neoadjuvant therapy for localized and locally advanced renal cell carcinoma

Ahmet Bindayi et al.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2018)

添加到收藏夹

Review Urology & Nephrology

Metabolic reprogramming in clear cell renal cell carcinoma

Hiromi I. Wettersten et al.

NATURE REVIEWS NEPHROLOGY (2017)

添加到收藏夹

Article Urology & Nephrology

Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience

Marc R. Matrana et al.

BJU INTERNATIONAL (2016)

添加到收藏夹

Article Oncology

Prognostic significance of two lipid metabolism enzymes, HADHA and ACAT2, in clear cell renal cell carcinoma

Zuohui Zhao et al.

TUMOR BIOLOGY (2016)

添加到收藏夹

Review Oncology

Evolving Immunotherapy Approaches for Renal Cell Carcinoma

Susanna A. Curtis et al.

CURRENT ONCOLOGY REPORTS (2016)

添加到收藏夹

Article Medicine, General & Internal

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

T. K. Choueiri et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Biochemistry & Molecular Biology

limma powers differential expression analyses for RNA-sequencing and microarray studies

Matthew E. Ritchie et al.

NUCLEIC ACIDS RESEARCH (2015)

添加到收藏夹

Article

Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge

Katarzyna Tomczak et al.

Wspolczesna Onkologia-Contemporary Oncology (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

A Subramanian et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.